Genentech 'breakthrough' GA101 doubles progression-free survival
This article was originally published in Scrip
Executive Summary
Genentech has filed for US and EU regulatory approval of GA101 (obinutuzumab) based on a doubling of median progression-free survival (PFS) versus the control group in a Phase III chronic lymphocytic leukemia (CLL) clinical trial.